US stock futures dip as Nvidia earnings spark little cheer
Investing.com - Jefferies initiated coverage on Cohance Lifesciences (COHANCE:IN) with a Buy rating and a price target of INR1,150.00 on Monday.
The research firm identified Cohance as a differentiated Contract Research Development and Manufacturing Organization (CRDMO) platform with specialized capabilities in antibody-drug conjugate (ADC) payloads, linkers, bioconjugation, and oligonucleotides.
Jefferies noted that Cohance maintains a global footprint across the United States and India, positioning it as a global leader in camptothecin-based payload manufacturing.
The firm expects Cohance to benefit from ADC industry tailwinds, supported by what it describes as a strong pipeline and multiple growth levers.
Jefferies projects Cohance will achieve 20% sales compound annual growth rate (CAGR) and 26% EBITDA CAGR over the fiscal years 2025 through 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.